MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance

Maki Kobayashi1,2,3,4 | Katsuhiko Kojima5 | Kazutaka Murayama6 | Yuji Amano5 | Takashi Koyama1,2 | Naoko Ogama1 | Toshikazu Takeshita5 | Tatsuro Fukuhara3,4 | Nobuyuki Tanaka1,2

1 Division of Tumor Immunobiology, Miyagi Cancer Center Research Institute, Natori, Japan
2 Division of Tumor Immunobiology, Tohoku University Graduate School of Medicine, Sendai, Japan
3 Division of Respiratory Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan
4 Department of Respiratory Medicine, Miyagi Cancer Center Hospital, Natori, Japan
5 Department of Microbiology and Immunology, Shinshu University School of Medicine, Matsumoto, Japan
6 Division of Biomedical Measurements and Diagnostics, Tohoku University Graduate School of Biomedical Engineering, Sendai, Japan

Correspondence
Nobuyuki Tanaka, Division of Tumor Immunobiology, Miyagi Cancer Center Research Institute 47-1 Nodayama, Medeshima-Shiode, Natori 981-1293, Japan.
Email: tanaka@med.tohoku.ac.jp

Abstract
IL-2 is a pleiotropic cytokine that regulates immune cell homeostasis. Its immunomodulatory function has been used clinically as an active immunotherapy agent for metastatic cancers. However, severe adverse effects, including the vascular leak syndrome and the preferential stimulation of anti-immunogenic Treg rather than effector T cells, have been obstacles. We newly designed a mutein IL-2, Mutakine-6 (MK-6), with reduced IL-2Rα–binding capability. MK-6 induced comparable cell growth potential toward IL-2Rβγ–positive T cells but was far less efficient in in vitro Treg proliferation and STAT5 activation. Unlike IL-2, in vivo administration of MK-6 produced minimal adverse effects. Using CT26 and B16F10-syngeneic tumor models, we found MK-6 was highly efficacious on tumor regression. Serum albumin conjugation to MK-6 prolonged in vivo half-life and accumulated in CT26 tumors, showing enhanced antitumor effect. Tumor-infiltrating leukocytes analysis revealed that albumin-fused MK-6 increased the ratio of effector CD8+ T cells to CD4+ Treg cells. These results demonstrated that MK-6 is an efficient immunomodulator potentially used for improved immunotherapy with decreased adverse effects and attenuated Treg stimulation.

KEYWORDS
cancer immunotherapy, cytokines, IL-2 Mutein, regulatory T cells, tumor-infiltrating lymphocytes

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; AUC, area under the curve; CT26, colon tumor 26; EC50, effective concentration 50; EPR, enhanced permeability and retention of macromolecules; IL-2, interleukin-2; IL-2Rs, interleukin-2 receptors; MSA, mouse serum albumin; TME, tumor microenvironment; TIL, tumor-infiltrating lymphocyte; Treg, regulatory T cells; VLS, vascular leak syndrome.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
1 | INTRODUCTION

IL-2 is a crucial cytokine maintaining the homeostasis of lymphocytes. The functions of IL-2 are pleiotropic, and it exerts both stimulatory and regulatory roles in the immune system. Functional IL-2 receptors (IL-2Rα) are either trimeric receptors composed of IL-2Rα (CD25), IL-2Rβ (CD122), and IL-2Rγ (the common cytokine receptor g chain; γc, CD132) chains or dimeric βγ IL-2Rs. Both of these receptor complexes transmit signals via the JAK3-STAT5 pathway. The trimeric IL-2Rαβγ forms high-affinity receptors with roughly 10-100 times higher affinity for IL-2 than the intermediate-affinity dimeric βγ IL-2Rs. Naïve CD8+ T, antigen-experienced (memory) CD8+ T, and natural killer (NK) cells express dimeric βγ IL-2Rs. IL-2Rα by itself serves as a low-affinity nonsignaling receptor, sequestering IL-2 in the tissue or contributing as an affinity converter for the intermediate IL-2Rs. Activated lymphocytes inducibly express IL-2Rα to form the trimeric αβγ IL-2Rs. In this regard, regulatory T cells (Tregs) are distinct for their constitutive positivity for high-affinity IL-2Rs. Thus, IL-2Rα expression is an active determinant on tissue distribution/sequestration of IL-2 and efficient signal transmission and a fate changer for responder cells.

The FDA approved a recombinant IL-2 (Aldesleukin) in 1992 as the first cancer immunotherapy agent in clinical use. The patients with metastatic melanoma and renal cell carcinoma who received high-dose IL-2 experienced a long-term impact on overall survival. Despite these outcomes, IL-2-based approaches often induce systemic toxicity, the vascular leak syndrome (VLS). Damage of endothelial cells and vasculatures leads to fatal vascular leakage resulting in multiple organ failures. Notably, direct interaction between IL-2 with IL-2Rα on endothelial cells in the lungs leads to severe pulmonary edema. The expansion of Treg by IL-2 seems to limit its therapeutic efficacy. Low dose IL-2 may affect the preferential proliferation of Treg rather than memory CD8+ T and NK cells, leading to an undesirable immune balance shift to antitumor immunity. Therefore, designing a “biobetter” IL-2 has been a challenge.

This study designed a genetically modified not-α-binding human IL-2 Mutein, Mutakine-6 (MK-6), MK-6 preserves CD8+ T cell proliferation potential without robust expansion of Treg. We demonstrate an improved Mutein property that upregulates the effector to Treg cell balance in preclinical models.

2 | MATERIALS AND METHODS

2.1 | Cell lines

293T and Expi293F were purchased from ATCC and Thermo Fisher Scientific, respectively. CT26, B16F10, and CTLL-2 were purchased from Riken Bioresource Center. I. Miyoshi provided MT-2, and T. Takeshita gifted TPA-Mat, TPA-Mat αKO, and KHYG-1. See Appendix S1 for detailed culture conditions, plasmids, and transfections.

2.2 | Mice

Female BALB/c and C57BL/6 mice, 6- to 7-week-old, were purchased from CLEA Inc. All mice were maintained under specific pathogen-free conditions following guidelines for animal experimentation. All animal studies were performed according to the guidelines of animal ethics and approved by the Miyagi Cancer Center Animal Care and Use Committee (permit number: MCCAE-2020-10 and AE.21.04).

2.3 | Homology modeling of MK-6, MK-9, and MK-18

We built the homology model of MK-6, MK-9, and MK-18 by using MODELLER with the standard protocol. The IL-2 structure (PDB-ID: 2ERJ, chain-D) was used for the template model to produce the sequence alignment between Thr3-Thr133 for IL-2 and Ala3-Thr133 for MK-6. We used MolFeat (FiatLux) to depict the molecular structures (ribbon and molecular surface models).

2.4 | In vitro T cell proliferation assay

We added indicated concentrations of Mutakines either to CTLL-2 or TPA-Mat cells. Seventy-two hours later, cell numbers were assessed as ATP content (CellTiter-Glo, Promega).

2.5 | STAT5 phosphorylation (pSTAT5) and Treg stimulation assays

We stimulated MT-2 (1 × 10^6) with Mutakines and performed Western blots as described previously using anti-STAT5 and anti-phospho-STAT5 (Tyr694; pSTAT5) Abs (CST). For ex vivo proliferation assays, we labeled Tregs with 5(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) and stimulated them with anti-CD3 and anti-CD28 Abs and increasing concentrations of Mutakines. Seventy-two hours later, CFSE dilution and the mean fluorescence intensity (MFI) of FoxP3 were determined. See Appendix S1 for Treg preparation.

2.6 | Assessment of treatment-associated toxicity in vivo

Either MK-0 (2.5, 25, and 250 μg) or MK-6 (2.5, 25, 100, and 250 μg) were intraperitoneally administered to BALB/c mice once a day for 4 days. On day 5, we sacrificed the mice to measure body weight, liver weight, and pulmonary wet to dry weight ratio using a miVac (SP Scientific). Oriental Yeast Ltd. determined serum aspartate transaminase (AST) and alanine transaminase (ALT) concentrations.
2.7 | Syngeneic mouse tumor models

CT26 cells (5 × 10⁵/mouse) were injected intradermally into the back of BALB/c. We caliper-measured tumor sizes and estimated the volume by the formula: \( V = 0.5 \times \text{shortest diameter}^2 \times \text{longest diameter} \). CT26-bearing mice were randomized on day 5 and administered with MK-6, MK-0, MSA-MK6, or MSA-MK0. For B16F10 melanoma models, 5 × 10⁶ B16F10 cells were injected intradermally into the back of syngeneic C57BL/6 mice. For details, see Appendix S1.

2.8 | Statistical analyses

Two-group datasets were analyzed by Student’s t-test (GraphPad Prism5). For three- or more-group analysis, one-way ANOVA followed by Tukey’s post hoc test and \( P = .05 \) was considered to be significantly different (\( P < .05, \quad \alpha < .01, \quad \alpha < .001, \quad \alpha < .0001 \)).

3 | RESULTS

3.1 | Design and screening for not-IL-2Rα-binding Mutakines

To obtain an IL-2 mutant (Mutakine) with attenuated Treg activation and adverse effects, we aimed to decrease IL-2Rα-binding capability. As a starting IL-2 protein template, we selected aaldesleukin-type IL-2 (MK-0) harboring a Thr 3 to Ala (T3A) and a C125A mutation that avoids O-glycosylation-dependent heterogeneity and aggregation.4,17 For the chase analysis, we fused NanoLuc to the C-terminus of IL-2, a portion not participating in any receptor interactions (Figure S1). By appending a signal sequence,18 we managed to purify the NanoLuc-MK-0 hybrid protein. Based on the crystal structure showing the human IL-2/IL-2R complex (Figure S2),4,19 multiple interactions between IL-2 and IL-2Rα, including K35A, F42A, Y45A, and L72G, were our significant targets for mutations (Figure S3). These critical residues on IL-2 are conserved between humans and mice, suggesting their significance in interface formation. We also paid attention not to interfere with the IL-2/IL-2Rβγ and IL-2/IL-2Rγ interactions. First, we confirmed that MK-0 possesses a binding capacity for mouse IL-2Rα and CTLL-2 proliferation potential, similar to wild-type IL-2 (MK-0) (Figure S4). We next performed an IL-2Rα-binding assay with candidate Mutakines to examine their reduction in α binding (Figure S5). We added NanoLuc-variant-IL-2 fusion proteins to the 293T expressing IL-2Rα (293Tα) or parental 293T (Figure S6) and evaluated Mutakine’s mouse IL-2Rα binding as an index of 293Tα to 293T (Figures 1A,B, S7). Among the 16 Mutakines, four candidates (MK-3, MK-5, MK-6, MK-13) were selected as low binders for IL-2Rα compared with the IL-2Rα binding of MK-0, and highly purified recombinant proteins were prepared (Figure S8A,B). Notably, MK-6 possesses four mutations, K35A/R38A/K43A/Y45A, localized on the IL-2/IL-2Rα interface showing little ability to bind IL-2Rα (mouse 293Tα/293T ratio; MK-0 vs MK-6 = 1425.6 vs 1.8, human 293Tα/293T ratio; MK-0 vs MK-6 = 1733.9 vs 5.2) (Figure 1A,B).

Similarly, we confirmed MK-13 with K35A/R38A/L72G mutations has almost lost its IL-2Rα-binding capability. Next, we checked the four candidates for their function. To confirm Mutakines’ growth-promoting capacity on T cells, we employed two IL-2-dependent lines, CTLL-2 and TPA-Mat, expressing mouse and human IL-2Rαβγ, respectively (Figures 1C,D, S9A-D, S10A). MK-3 with a slight residual IL-2Rα-binding capability rendered good growth potential to both CTLL-2 and TPA-Mat cells, similar to the effects of wild-type IL-2. The half-maximum effective concentration (EC₅₀) of MK-5, MK-6, and MK-13 was much higher than IL-2, ranging from 0.88 to 11.1 nmol L⁻¹ for CTLL-2 cells. For TPA-Mat, these three Mutakines also gave a higher EC₅₀ of 0.066 to 4.3 nmol L⁻¹. Based on the minimum IL-2Rα-binding capacity and partial cell proliferation ability on both mouse and human T cells, we finally selected MK-6. The half-maximum EC₅₀ of MK-6 was increased compared with MK-0 on mouse CTLL-2 (EC₅₀ MK-0 0.047 nmol L⁻¹, EC₅₀ MK-6 3.37 nmol L⁻¹) (Figure 1C), which was similar to that on human TPA-Mat (EC₅₀ MK-0 0.037 nmol L⁻¹, EC₅₀ MK-6 2.0 nmol L⁻¹) (Figure 1D). Next, we performed proliferation assays using two IL-2Rαβγ-expressing cell lines, KHYG-1 and TPA-Mat oKO (Figure S10B,C). EC₅₀ MK-0 and EC₅₀ MK-6 toward these two cells were similar (Figures 1E,F). Furthermore, to compare MK-6 with other IL-2 muteins, we performed experiments using MK-9, MK-18, and MK-19 carrying the IL-2 mutations from previously reported three muteins, CEA-IL2v,20 human IL-2 mutein,21 and superkine,22 respectively (Figure S11A-G). The results showed that MK-19 has a residual partial affinity toward IL-2Rα, while MK-6, MK-9, and MK-18 have lost the binding capability (Figure S11B,C). The latter three muteins possess comparable growth potential on human IL-2Rαβγ-expressing cells (Figure S11D,E). Interestingly, MK-9 and MK-18 could not support murine T cell growth at all (Figure S11G). Taken together, we found MK-6 is one of the best Mutakine in terms of negligible IL-2Rα-binding capacity, but it possesses comparable growth potential toward both human and mouse IL-2Rαβγ-expressing cells from the aspect of Emax value.

3.2 | Structural basis of MK-6 for not-IL-2Rα-binding capability

To verify a structural basis of MK-6 for its inability to bind IL-2Rα, we performed a computer-assisted 3D simulation based on the previously reported crystal structure of the quaternary IL-2-IL-2Rα-IL-2Rγ complex. IL-2 binds to IL-2Rα through hydrogen bonds and Van der Waals contacts between K35, R38, K43, and Y45 localized on the AB loop of the IL-2 surface and IL-2Rα (Figure 2A). The mutations of K35A, R38A, K43A, and Y45A remove large parts of Van der Waals’s interaction surface, rendering ineffective binding to IL-2Rα without changing the native IL-2 structure (Figure 2B). Therefore, the overall design of the MK-6–IL-2Rαβγ complex remains essentially similar to the wild-type quaternary complex.
3.3 | MK-6 attenuated Treg function in vitro and ex vivo

To examine whether MK-6 has a lower proliferating potential on Treg, we first used human MT-2 cells, showing several Treg characteristic markers, such as FoxP3\(^+\)CD25\(^+\)CD4\(^+\). With its human IL-2R\(\alpha\beta\gamma\) expression and suppressive effects on T cells (Figure S12A–E), we and others regarded MT-2 as a human Treg-like cell line.\(^{23}\) We stimulated MT-2 with a titrated dose of MK-0 and MK-6 and examined pSTAT5 at a lower amount of MK-0 (0.001 nmol L\(^{-1}\)). MK-0 increased the phosphorylation levels in a quantity-dependent manner up to 10 nmol L\(^{-1}\) (Figure 3A). MK-6, however, induced minor if any pSTAT5 even at a higher concentration of 10 nmol L\(^{-1}\). Thus, MK-6 exhibited weaker IL-2-signaling potential on a human Treg-like cell compared with the control.

Next, we examined whether MK-6 affects ex vivo Treg proliferation using mouse peripheral CD25\(^+\)CD4\(^+\) Treg cells isolated from the spleen. We incubated cells with various doses of MK-6 or MK-0 in the presence of anti-CD3/CD28 and monitored cell division by dilution of incorporated CFSE dye. MK-0 initiated Treg cells’ proliferation as low as 1 pmol L\(^{-1}\), and 10 pmol L\(^{-1}\) MK-0 showed a significant CFSE-low fraction appearance (Figure 3B: upper). However, 10 pmol L\(^{-1}\) of MK-6 induced minor cell division on Treg, and even 1 nmol L\(^{-1}\) MK-6 was ineffective. Indeed, we observed Treg cells’ proliferation at a very high MK-6 concentration of 10 nmol L\(^{-1}\) (Figure 3B: lower). Thus, MK-6 presents a significantly weaker ability on Treg proliferation compared...
with that of MK-0. Next, we examined whether MK-6 possesses attenuated induction of FoxP3, a transcription factor playing critical roles in the regulatory function in Treg. Cells stimulated with 1 nM of MK-0 enhanced FoxP3 protein amount, with elevated MFI of 451 from the PBS control value of 159. However, the same dose of MK-6 induced a negligible increase in FoxP3 MFI (170), suggesting that MK-6 is a poor FoxP3 inducer for committed Tregs (Figure 3C). Taken together, we found MK-6 possesses attenuated stimulating effects on Treg.

3.4 | MK-6 administration induced elevation of CD8+ T to Treg ratio in spleen compared with IL-2

Next, we asked whether MK-6 has a weaker Treg expansion potential than MK-0 in vivo. We intraperitoneally administered the Mutakines to tumor-free mice and analyzed splenic immune cells (Figure 4A). Low-dose MK-0 (25 μg/head, once daily for four consecutive days) induced a mild increase of FoxP3+CD25+ Treg, and we saw a significant growth of Treg after the 250-μg treatment (Figure 4B). However, dose escalation studies with MK-6 showed slight Treg expansion, remaining almost unchanged from the PBS controls. We also examined splenic CD8+ T and DX5+ CD3+ NK cells. Somewhat unexpectedly, we did not find any difference between MK-0 and MK-6 in the two cell populations’ expansion (Figure 4C,D). Finally, we evaluated the CD8+ T to Treg ratio, indicative of a cytotoxic immune environment. The low-dose MK-0 (25 μg) treatment exhibited a mild decrease in the CD8+ T to Treg ratio, and we observed a significant reduction by the high-dose MK-0 (250 μg) administration. However, the CD8+ T to Treg cells ratio did not decline even by the same high amount of MK-6 (Figure 4E). Collectively, these results demonstrate that MK-6 possesses the capability to upregulate the CD8+ T to Treg ratio in vivo.

3.5 | MK-6 decreased IL-2 administration–associated adverse effects in mice

IL-2Ra has a broad expression profile, most notably on vascular endothelial cells. Because MK-6 had lost IL-2Ra–binding ability, we expected that MK-6 would reduce toxicity associated with IL-2 administration. To evaluate the correlation between MK-6’s IL-2Ra–binding capacity and adverse effects in vivo, we administered titrated doses of MK-0 and MK-6 to tumor-free mice (Figure 4A,F-J). We evaluated mice for body weight, pulmonary edema, and hepatic function. All of them consist of hallmarks of IL-2 therapy–associated adverse effects called experimentally induced VLS. MK-0 treatment induced body weight gain, pulmonary edema, and liver weight increase in a dose-dependent manner (Figure 4F-H). By contrast, we barely observed these adverse effects in mice injected with MK-6, remaining largely asymptomatic like the PBS controls. Two markers for liver injury, AST and ALT, revealed no differences to controls across all treatment groups (Figure 4I,J). Together, these results indicate that MK-6 administration does not induce severe systemic toxicity, often associated with IL-2 immunotherapy.

3.6 | MK-6 immunotherapy is efficacious in syngeneic tumor models

Next, we examined the antitumor efficacy of MK-6 using mouse syngeneic tumor models. First, CT26 tumor-bearing mice were administered 25 μg of MK-0 and MK-6 once daily for seven consecutive days (Figure S13). However, this equal dose of MK-6 and MK-0 did not significantly affect CT26 tumors, irrespective of the IL-2Ra binding. Besides, before the assay, all the mice injected with 25 μg of MK-0 manifested lower robustness, such as shivering and less mobility (data not shown). A dose escalation study achieved an excellent CD8+ T cells to Treg ratio by 100 μg MK-6 (Figure 4E). The T cell proliferation potential of MK-6 was much lower than that of MK-0 (Figure 1C,D); we adjusted the dosage of MK-0 so that it exerts the same EC_{50} value against trimeric αβγ IL-2Rs with that of MK-6. Altogether, 5 μg of MK-0 or 100 μg of MK-6, equivalent amounts for the high-affinity IL-2Rs, were injected twice a day intraperitoneally into the CT26 tumor-bearing mice (Figure 5A). MK-6
injection induced slight retardation of tumor growth on day 7 and significant tumor volume suppression on day 11, compared with PBS controls and MK-0. All the mice were devoid of unhealthy conditions throughout the experiments, suggesting that the respective doses of MK-6 and MK-0 were tolerable. We also monitored adverse effects on day 12. MK-0–treated tumor-bearing mice significantly increased liver weight compared with those with PBS or MK-6 injection (Figure S14A), but serum AST and ALT levels remained unaltered (Figure S14B,C). By contrast, both MK-6 and MK-0 induced body weight gain (Figure S14D), and neither MK-6 nor MK-0 treatment induced pulmonary edema (Figure S14E). Collectively, MK-6 treatment at the EC$_{50}$-referenced dose exhibited therapeutic effects in the CT26 syngeneic tumor model, and we managed to avoid the adverse impact of high-dose MK-6.

3.7 | Albumin-conjugated MK-6 improved pharmacodynamics while maintaining therapeutic functions

One of the disadvantages of IL-2 therapy is its short half-life in vivo, less than 30 minutes.26,27 We noticed that the addition of NanoLuc to IL-2 may moderately affect IL-2’s longevity, which was still not satisfactory. We selected mouse serum albumin (MSA) to stabilize Mutakines and avoid potential outcomes from the artificial fusion partner. We fused it to the C-terminus of MK-6 via a flexible linker (Figure S1B). The serum half-life of MSA-MK-6 (5.6 hours) was approximately twice that of MK-6 (2.9 hours), and we could detect MSA-MK-6 up to 120 hours after the intravenous injection, resulting in its 15 times higher estimated AUC than that of MK-6 (Figure

**FIGURE 3** MK-6 has a weaker ability for proliferation and induction of Treg cells in vitro and ex vivo. A, Upper: Western blot analyses showing the expressions of STAT5 phosphorylation (pSTAT5) in MT-2 after Mutakines’ activation. Cells were left unstimulated or stimulated with MK-0 and MK-6 for 15 min and lysed and immunoblotted with anti-pSTAT5 (top) or anti-STAT5 (bottom) Abs. Lower: quantification bar graphs of blot analysis. n = 2 per group. B, Expansion of Treg in vitro. We cultured 5(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled, bead-sorted Treg cells with MK-0 and MK-6 at indicated concentrations for 72 h. C, Left: intracellular staining showing the level of FoxP3 expression by bead-sorted Tregs further expanded with MK-0 (dark gray–filled) and MK-6 (bright gray–filled). Isotype (open) and control (dashed line). Right: mean fluorescence intensity (MFI) values for FoxP3. n = 3 per group. Data show means + SEM. NS, not significant.
We next examined the in vivo effect of MSA-MK-6 using tumor-bearing mice. Considering the 20-fold difference in high-affinity IL-2 binding, we determined dosing conditions for MSA-MK-6 and MSA-MK-0 to exert equivalent effects of IL-2 signaling. Also, our preliminary experiments have suggested an extension of the intraperitoneal administration interval of MSA-MK-6 up to 96 hours. Accordingly, CT26 tumor-bearing mice received two intraperitoneal injections of 10 μg of MSA-MK-0 or 200 μg of MSA-MK-6 on days 5 and 10 after the tumor implantation (Figure 5B). All the mice tested remained healthy throughout the study. MSA-MK-0 and MSA-MK-6 significantly suppressed the growth of CT26 tumors, and the efficacy of MSA-MK-6 was comparable to that of MSA-MK-0. We also checked B16F10 melanoma tumors. The MSA-MK-6 and MSA-MK-0 showed similarly high efficacy compared with that of PBS (Figure 5C). The tumor-infiltrating lymphocyte (TIL) analysis revealed that MSA-MK-6–treated CT26 tumors contained...
substantially more CD3$^+$ T cell populations (Figure 5D). In contrast, FoxP3$^+$CD25$^+$ Treg infiltration was attenuated considerably by the MSA-MK-6 treatment, compared with the same population by the MSA-MK-0 or PBS (Figure 5E). MSA-MK-6 treatment enhanced the CD8$^+$ T cells to Treg cells ratio in TILs, compared with PBS or MSA-MK-0 treatments (Figure 5F). Using a fusion partner albumin, MK-6 increased its stability and exerted its antitumor activity in vivo even by the 4-day-interval administrations. Furthermore, albumin may contribute to tumor targeting of MK-6. To examine such drug delivery effects, we used NanoLuc-fused MSA-MK-6 to observe

![Graphs and images showing tumor volume, CD3$^+$ T cells, Treg cells, CD8$^+$/Treg ratio, luminescence, and FACS analysis for different treatments: PBS, MSA-MK-0, and MSA-MK-6.](image)
pharmacokinetics. First, we asked for direct binding of MSA-MK-6 to tumor cells, but it did not show an increase in any association with CT26 in vitro (Figure 5G). We next proceeded to the in vivo study. MK-6 or MSA-MK-6 was injected intraperitoneally into the CT26 tumor model. Twenty-four hours after injection, we harvested the tumors and measured the luciferase activities. The intratumor uptake of MSA-MK-6 was considerably higher than that of MK-6 (Figure 5H). These data demonstrate that a significant amount of MSA-MK-6 remains within the tumor even 24 hours after injection.

4 | DISCUSSION

Here, we developed a genetically modified IL-2, MK-6, with partial T cell proliferation potential. By diminishing the IL-2Rα binding, MK-6 gained two significant advantages. First, MK-6 administration reduced inevitable toxicity associated with high-dose IL-2 therapy. Second, MK-6 attenuated anti-immunogenic Treg expansion. Accordingly, MK-6, especially when fused with albumin, exerted an antitumor effect in syngeneic mouse tumor models without apparent significant adverse effects.

We designed MK-6 carrying four mutations over the aldesleukin-type IL-2. There are several attempts to manipulate IL-2, leading to CD8α binding, MK-6 gained two significant advantages. First, MK-6 administration reduced inevitable toxicity associated with high-dose IL-2 therapy. Second, MK-6 attenuated anti-immunogenic Treg expansion. Accordingly, MK-6, especially when fused with albumin, exerted an antitumor effect in syngeneic mouse tumor models without apparent significant adverse effects.

We speculated MK-6 worked efficaciously in vivo because it in-
Treg would improve therapeutic efficacy. A crucial feature of Tregs is that they express high-affinity IL-2Rαβγ, yet they do not produce IL-2. Tregs, instead, highly rely on exogenous IL-2 produced by neighboring activated T cells for their survival and proliferation via the JAK3/STAT5 signaling pathway. IL-2Rα expression is enhanced in activated Tregs, creating a positive feedback mechanism to favor IL-2Rα Tregs. On the contrary, IL-2–deprived CD8+ T cells cannot proliferate due to the IL-2 consumption by Tregs. Accordingly, several reports have demonstrated a tight association of Treg proliferation with insufficient IL-2 therapy, and Treg depletion improves IL-2–induced antitumor immunity. These results highly suggest that IL-2 immunotherapy demands a concomitant Treg suppression strategy. Adding MK-6 to the TME should change the balance of CD8+ T and Treg cells controlling the two cell populations’ survival and functions. Interestingly, MSA-MK-6 administration increased CD3 and CD8+ T cell infiltration in the TME. The albumin-fused MK-6 seems to alter immunologically “cold” tumors into “hot” and creates an antitumor environment by relatively reducing the effect of Treg in a desert-type TME.

The stability of IL-2 has been another significant factor to improve the clinical efficacy, for IL-2 receives rapid renal clearance resulting in its short half-life. In this study, we managed to give MK-6 durable stability by fusing it with serum albumin. Albumin has an extraordinary half-life of almost 3 weeks in vivo. The maximum serum concentration of albumin-fused MK-6 (MSA-MK-6) was higher than that of MK-6, making a dramatic increase in the AUC. Accordingly, we could reduce the administration interval so that only two intraperitoneal shots of MSA-MK-6 worked even better for CT26 tumor shrinkage than series of twice-daily injections of its prodrug, MK-6.

Furthermore, albumin often accumulates at tumor sites and inflamed tissues. These attractive properties of albumin make it favorable for its drug delivery vehicle. In sarcoma therapy, for instance, doxorubicin’s cardiac toxicity has limited its clinical use. By conjugating with human serum albumin, aldoxorubicin (INNO-206) reduced cardiac toxicity and improved its tumor-specific accessibility. In this study, MSA-MK-6 did not directly bind CT26 cells in vitro, but a substantial amount of MSA-MK-6 accumulated in CT26 tumors. Efficient albumin earnings within tumors have been well documented and termed the “enhanced permeability and retention of macromolecules (EPR) effect.” The leakage of cancer-associated endothelium explains the phenomenon of tumor interstitium and molecules’ movement within fluids. Although our present works did not uncover an aspect of active MSA-MK-6 uptake into tumors, one could speculate that the EPR effect might elevate its intratumor transport. The pronounced antitumor activity of MSA-MK-6 suggests that it is an attractive agent to induce antitumor immunity with relatively long bioavailability.

The present study’s main limitations are the different weight doses of modified IL-2, affecting the therapeutic outcomes. Our experimental design used 20 times more MK-6 than the prototype form MK-0 in the syngeneic tumor models. We designed the dosages so that each dosage supports equivalent growth and signaling on high-affinity IL-2R–expressing cells; differences adjusted for MK-6 and MK-0 considering (a) EC50 in growth assays on trimeric αβγ IL-2Rs–expressing T cells and (b) pSTAT5 of Treg-like MT-2 cells. Notably, MK-6 did not cause any dose-dependent systemic toxicity associated with IL-2Ra, and the higher dose given to mice was well tolerable. Safety of high-dose MK-6 treatment would benefit from developing a new IL-2–associated therapy in the future.

In conclusion, we have developed a not-α IL-2, MK-6, devoid of IL-2’s severe adverse effects in vivo. Albumin-fused MK-6 showed a significant antitumor impact by enhancing the CD8 to Treg ratio of the. Our current results of IL-2–based therapy may pave the way for the development of effective cancer immunotherapies.

ACKNOWLEDGMENTS
This work was supported by Grants-in-Aid for Scientific Research (B) (18H02701) and (C) (18K08643, 18H04056, 19K08609, 20K08580, and 20K08203) from the Japan Society for the Promotion of Science, Grants-in-Aid from JST-CREST (JPMJCR17H4), and the Project for Cancer Research and Therapeutic Evolution from the Japan Agency for Medical Research and Development (21cm0106387h0001). We thank the Biomedical Research Core of the Tohoku University Graduate School of Medicine for technical support and H. Kosai and N. Ishizawa for technical assistance.

DISCLOSURE
The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS
MK, KK, KM, TT, TF, and NT designed the research; MK, KK, KM, TT, TF, and NT provided 3D and data analyses. MK, KK, KM, TT, TF, and NT wrote the paper; MK, KT, and KK performed cell culture, molecular biology, and several experiments; and KM provided 3D data analyses.

ORCID
Yuji Amano https://orcid.org/0000-0002-1588-3120
Tatsuro Fukuhara https://orcid.org/0000-0003-0440-470X
Nobuyuki Tanaka https://orcid.org/0000-0002-0229-8061

REFERENCES
1. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;32:153-165.
2. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12:180-190.
3. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38:13-25.
4. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gamma receptors. Science. 2005;310:1159-1163.
5. Sugamura K, Asao H, Kondo M, et al. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol. 1996;14:179-205.
6. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 1993;73:5-8.
11. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2.

12. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic cancer with recombinant interleukin-2.

13. Kriegl C, Letourneau S, Panteleev G, Boyman O. IL-2 and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol. 2009;123:758-762.

14. Gajewski TF, Woo SR, Zha Y, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013;25:268-276.

15. Salik A, Blandell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779-815.

16. Watanuki Z, Kosai H, Osanai N, et al. Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling. Biochem Biophys Res Commun. 2014;455:269-276.

17. Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. 1993;46:446-514.

18. Hall MP, Unch J, Binkowski BF, et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazine substate. ACS Chem Biol. 2012;7:1848-1857.

19. Staub DJ, Debler EW, Horton PA, Smith KA, Wilson JA. Crystal structure of the IL-2C signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci USA. 2006;103:2788-2793.

20. Klein C, Waldhauer I, Nicolini VG, et al. Cergutuzumab amunaleucin (F42A mutant of human interleukin 2). A conjugate of interleukin-2 receptor alpha subunit.

21. Carmenate T, Pacios A, Enamorado M, et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol. 2013;190:6230-6238.

22. Levin AM, Bates DL, Ring AM, et al. Exploiting a natural conformation switch to engineer an interleukin-2 ‘superkine’. Nature. 2012;484:529-533.

23. Hamano R, Wu X, Wang Y, Oppenheim JJ, Chen X. Characterization of MT-2 cells as a human regulatory T cell-like cell line. Cell Mol Immunol. 2015;12:780-782.

24. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986;137:1735-1742.

25. Ballmer-Weber BK, Dummer R, Kung E, Burg G, Ballmer PE. Interleukin-2-induced increase of vascular permeability without decrease of the intravascular albumin pool. Br J Cancer. 1995;71:78-82.

26. Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36:763-777.

27. Lotze MT, Matory YL, Etinghausen SE, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol. 1985;135:2865-2875.

28. Arenas-Ramirez N, Zou C, Popp S, et al. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med. 2016;8:367ra166.

29. Spangler JB, Tomala J, Luca VC, et al. Antibodies to Interleukin-2 Elicit Selective T cell subset potentiation through distinct conformational mechanisms. Immunity. 2015;42:815-825.

30. Charych DH, Hoch U, Langowski JL, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22:680-690.

31. Mott HR, Baines BS, Hall RM, et al. The solution structure of the F42A mutant of human interleukin 2. J Mol Biol. 1995;247:979-994.

32. Grant AJ, Roessler E, Ju G, Tsudt M, Sugamura K, Waldmann TA. The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit. Proc Natl Acad Sci USA. 1992;89:2165-2169.

33. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst. 2003;95:741-749.

34. Nakagawa K, Miller FN, Sims DE, Lentsch AB, Miyazaki M, Edwards MJ. Mechanisms of interleukin-2-induced hepatic toxicity. Can Res. 1996;56:507-510.

35. Sun Z, Ren Z, Yang K, et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control. Nat Commun. 2019;10:3874.

36. Viguier M, Lemaire F, Verola O, et al. Foxp3 expressing regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.

37. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.

38. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells. Annu Rev Immunol. 2004;22:680-690.

39. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells. Annu Rev Immunol. 2004;22:680-690.
47. Bern M, Sand KM, Nilsen J, Sandlie I, Andersen JT. The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery. J Control Release. 2015;211:144-162.

48. Wunder A, Muller-Ladner U, Stelzer EH, et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol. 2003;170:4793-4801.

49. Kratz F, Abu Ajaj K, Warnecke A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin Investig Drugs. 2007;16:1037-1058.

50. Cranmer LD. Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date. OncoTargets Ther. 2019;12:2047-2062.

51. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor-tropic accumulation of proteins and the antitumor agent smancs. Can Res. 1986;46:6387-6392.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Kobayashi M, Kojima K, Murayama K, et al. MK-6, a novel not-$\alpha$ IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance. Cancer Sci. 2021;112:4478-4489. https://doi.org/10.1111/cas.15127